Isomorphic Labs Raises $2.1B for AI-Powered Drug Discovery, Backed by Alphabet and Sovereign Wealth Funds
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Bigstock While much of the conversation about artificial intelligence revolves around images, virtual assistants or automation, Demis Hassabis has a look at something much more ambitious. Google's co-founder DeepMind announced an investment of up to $2.1 billion to boost the development of AI drugs and accelerate the search for treatments capable of dealing with diseases that for decades have challenged medicine.
Isomorphic Labs raises $2.1B for AI-powered drug discovery, backed by Alphabet and sovereign wealth funds
Isomorphic Labs' funding highlights AI's potential to revolutionize drug discovery, but success hinges on bridging computational and clinical gaps. The post Isomorphic Labs raises $2.1B for AI-powered drug discovery, backed by Alphabet and sovereign wealth funds appeared first on Crypto Briefing.
Isomorphic Labs, a spinoff from Alphabet and founded by Google DeepMind CEO Demis Hassabis, has raised $2.1 billion in a Series B funding round. This round brings the total outside investment in the project to approximately $2.6 billion. In fact, the market is fundamentally betting that Isomorphic can become as iconic for the pharmaceutical sector as... The post Alphabet invests $2.1 billion in Demis Hassabis's AI platform for next-generation dr…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
